Navigation Links
Insmed CEO to Present at Drug Discovery & Development Conference
Date:7/25/2008

CEO Geoffrey Allan Will Discuss Company's IPLEX(TM) Program in Myotonic

Muscular Dystrophy

RICHMOND, Va., July 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present at IBC's 13th Annual Drug Discovery and Development of Innovative Therapeutics on Thursday, August 7th, 2008 at 9:25 AM ET.

Dr. Allan will be participating in the Orphan Diseases track of the conference and his presentation will be entitled, "Myotonic Muscular Dystrophy - A Major Unmet Medical Need." He will present Insmed's progress with its Phase II trial for IPLEX(TM) in Myotonic Muscular Dystrophy. The trial, which has seen strong patient and physician interest, is now fully enrolled. It is a six month, randomized, double-blind, placebo-controlled trial being conducted at 13 research centers across the U.S.

The conference will be held from August 4th to August 7th, 2008, at the World Trade Center Boston and the Seaport Hotel in Boston, MA.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause act
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Insmed to Host Second Quarter 2008 Conference Call
2. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
3. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
4. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
5. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
6. Insmed Announces First Quarter 2008 Financial Results
7. Insmed to Present at CBI Follow-On Biologics Conference
8. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Techne Corporation (NASDAQ: ... agreed to acquire 100% ownership of Bionostics Holdings ... Bionostics is a global leader in the development, ... the proper operation of in vitro ... care blood glucose and blood gas testing.  Biosnostics ...
(Date:6/18/2013)... WOODLANDS, Texas , June 18, 2013 /PRNewswire/ ... LXRX ), a biopharmaceutical company focused on discovering ... John Northcott has joined the company ... and operations. Mr. Northcott brings extensive commercial experience ... commercialization across a variety of therapeutic areas. ...
(Date:6/18/2013)... Ontario (PRWEB) June 18, 2013 ... in Proof of Concept and Phase I-IV clinical ... strategic alliance with Northern Air Environmental Technologies (NAET), ... for the deployment, monitoring, and servicing of mobile ... and Ocular clinical trials. , ...
(Date:6/18/2013)... ActiGraph, a leading provider of objective physical ... community, announced today that Dr. Victor KR Matsudo has ... Scientific Director of the Physical Fitness Research Center of ... at Gama Filho University and the Chairman of the ... of Health of São Paulo State, Brazil. , ...
Breaking Biology Technology:Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board 2
... BOSTON, Jan. 4 Follica Inc., a privately ... (male and female pattern hair,loss caused by androgens ... follicle disorders, today announced a $5.5 million Series ... existing,investors PureTech Ventures participated. The funding is expected ...
... Program Called ... ... GEN),announced today a new pre-clinical antibody program called HuMax-CD32b(TM).,This fully ... and hematological tumors. HuMax-CD32b may have therapeutic potential,in the treatment ...
... (Oct. 31, 2007) -- In the face of terrorism ... improve survival for critically injured patients are more vital ... underlying these systems -- such as the notion that ... the hospital first -- have rarely been subjected to ...
Cached Biology Technology:Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic 2Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic 3Genmab Announces HuMax-CD32b Pre-Clinical Program 2Genmab Announces HuMax-CD32b Pre-Clinical Program 3Triage study challenges notions of emergency medical response to disaster 2Triage study challenges notions of emergency medical response to disaster 3Triage study challenges notions of emergency medical response to disaster 4
(Date:6/18/2013)...  Paris Air Show – Marvin Test ... a leading provider of innovative test solutions for ... solutions this week at the Paris Air ... including increasingly complex armament systems with longer lifecycles, ... test solutions that address legacy system obsolescence. Marvin ...
(Date:6/18/2013)... Faculty of Medicine have discovered a mechanism that is ... a component of blood typically associated with clotting, were ... detection, seal it off from the rest of the ... Immunology this week, provide the science community with ... has known that platelets do participate in immunity, but ...
(Date:6/18/2013)... Department,s National Renewable Energy Laboratory (NREL), and the ... describing a novel cellulose-degrading enzyme from a marine ... as the gribble. , Gribbles are biologically ... to produce their own enzymes instead of using ... eat. New biomass-degrading enzymes from novel sources such ...
Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Immunity mechanism discovered 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2
... at Oregon State University has used a new method ... in Oregon with high numbers of methamphetamine-related problems per ... illegal drug. The study, presented today at a ... then identified five counties with the most meth-linked incidents ...
... Although cancer remains a leading cause of death in America, ... new anti-cancer agent before the FDA and the success rate ... many research hours and dollars are wasted chasing avenues that ... Translational Research Working Group (TRWG) developed a set of tools ...
... number of cancer-causing genes already identified, many more remain ... linked a previously unsuspected gene, CDK8, to colon cancer. ... made possible by new tools for assessing the activity ... study. As these tools are further improved, the stream ...
Cached Biology News:New method identifies meth hot spots 2New method identifies meth hot spots 3New tool to speed cancer therapy approval available 2Researchers identify cancer-causing gene in many colon cancers 2
Prepared from plasminogen by activation with immobilized human uPA...
Human FADD Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
... triple quadrupole 1200L sets the new ... environment - incorporating the latest technologies ... liquid chromatography analytical needs. The ... the Transmission Quadrupole Analyzer provide superior ...
Biology Products: